Plus Therapeutics appoints Chief Development Officer

Plus Therapeutics has appointed Eric J. Daniels, M.D., MBA, as its new Chief Development Officer. Dr. Daniels brings extensive experience in clinical development, regulatory strategy, and corporate operations to the role. His appointment is expected to strengthen the company's execution capabilities as it advances its clinical pipeline. This strategic hire signals a commitment to accelerating drug development and navigating the complex regulatory pathways in the biotechnology sector.